German market leader within a few years

Business development

M1 has a clear growth strategy within the established business model. Since the opening of our first location in Berlin in 2012, we have continuously developed. Today, M1 is the market leader in Germany and has started the international expansion. In the coming years we will open numerous new locations in Germany and roll out the successful their model internationally. We see great potential in practically every country in Western Europe and beyond. After all, the markets for cosmetic surgery are very fragmented and prices are too high.

In addition, we see potential in other areas of aesthetic and plastic medicine and, from a medical point of view, the demand for specialization. That, we want to take advantage of.


Outlook: targets by the end of 2023

Growth targets

  • to operate approx. 100 M1 Med Beauty outpatience clinics
  • to further increase inpatient clinic capacities
  • to be a leading lifestyle brand in aesthetic medicine
  • to be internationally known with our own brand for medical cosmetics

 

Latest news

| Corporate News

In contrast to the worsening pandemic situation, M1 Kliniken AG continues to record strong demand. The number of injection treatments and surgical treatments performed in the German market in the 3rd quarter of 2020 rose by almost 20% year-on-year to over 65,000.

| Corporate News

  • Group revenues decrease by only 12 % to 29.1 million Euro despite loss of about 1/3 of treatment days
  • Consolidated net income of 2.0 million Euro
  • High utilization of the specialized centers after resumption of patient treatments

| Corporate News

Yesterday, M1 Kliniken AG successfully held its Annual General Meeting 2020. In his presentation, the Management Board gave an outline of the company's prosperous development in the 2019 financial year, which was accompanied by a significant …

| Corporate News

M1 Kliniken AG acquires about 48 % of the share capital of HAEMATO AG from MPH Health Care AG. Transfer of the HAEMATO shares within the framework of a capital increase through contribution in kind Focus of both companies on their respective core …